BYAH
resolvedPark Ha Biological Technology Co., Ltd.
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
BYAH (Park Ha Biological Technology Co., Ltd.) gapped up an extraordinary 487% from $0.46 to $2.70 and has since extended to $4.03, suggesting an aggressive short-term repricing event. However, the absence of fundamental data—including earnings results, guidance, market cap, and financial statements—makes it impossible to assess whether this move is supported by genuine fundamental improvement. The company's classification as Consumer Defensive while carrying a Biological Technology name adds confusion about its actual business model, and the lack of analyst coverage or institutional ownership data suggests this is a micro-cap or nano-cap security with extremely limited Wall Street following. The 2x volume spike, while significant, is relatively modest for a 487% gap, indicating extremely thin liquidity and a low float rather than broad institutional accumulation. Stocks with this profile—sub-dollar names gapping hundreds of percent on limited information—are typically driven by retail speculation, news catalysts (regulatory approval, distribution deal, reverse merger), or promotional activity rather than fundamental earnings-driven repricing. The probability of a sustained rerating is LOW without verifiable fundamental catalysts, and the risk of a sharp reversal is HIGH given the absence of institutional support, reliable financials, or a proven business model. Investors should treat this as a speculative event requiring extreme caution.
Analyzed by rerate-v2+glm-5.2 · Aug 6, 2026
Catalysts
- Potential regulatory approval, product launch, or distribution partnership in biological/health products that could materially expand revenue
- Possible reverse merger, acquisition, or change in business direction that fundamentally alters the company's trajectory
- Micro-cap dynamics: extremely low float and thin liquidity can amplify any news into outsized percentage gains
- If the company operates in traditional medicine or health supplements (consumer defensive), a major contract or geographic expansion could justify repricing
Risks
- No verifiable earnings data, financial statements, or guidance to support the 487% gap—pure speculation risk
- Extremely high probability of a sharp reversal given thin volume (only 2x average) supporting a massive percentage move
- Chinese small-cap listing risks: regulatory uncertainty, audit oversight concerns (HFCAA), and potential delisting risk
- Possible pump-and-dump or promotional activity given the sub-dollar starting price and limited public information
- No institutional ownership or analyst coverage to provide price stability or fundamental validation
- Unknown business model and sector classification ambiguity raises governance and transparency concerns
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| Day 1 | $3.14 | $3.50 | $2.81 | 556.1K |
| Day 2 | $3.45 | $3.95 | $3.01 | 428.1K |
| 📍 Day 3 | $3.55 | $3.77 | $3.28 | 132.7K |
| Day 4 | Pending | |||
| Day 5 | Pending | |||
Signal Breakdown
Gap partially filled (25%) — ambiguous
Volume dropped 76% from day 1 — no institutional follow-through buying
Higher highs with peak close on day 3 — continued buying interest
Drew down 30.3% from gap close — significant give-back
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026